Citadel Advisors
FSTX

Citadel Advisors’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Citadel Advisors’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-49,708
Closed -$255K – 15756
2022
Q3 		$255K Sell
49,708
-159,687
-76% -$1M ﹤0.01% 9933
2022
Q2 		$1.31M Sell
209,395
-83,598
-29% -$282K ﹤0.01% 6420
2022
Q1 		$1.04M Buy
292,993
+18,893
+7% +$69.8K ﹤0.01% 7599
2021
Q4 		$1.38M Buy
274,100
+14,455
+6% +$87.2K ﹤0.01% 7097
2021
Q3 		$1.9M Sell
259,645
-183,135
-41% -$1.26M ﹤0.01% 6492
2021
Q2 		$3.8M Buy
442,780
+407,622
+1,159% +$3.48M ﹤0.01% 5039
2021
Q1 		$1K Buy
+35,158
New +$341K ﹤0.01% 13104
2020
Q4 		– Sell
-15,586
Closed -$84K – 11728
2020
Q3 		$84K Buy
+15,586
New +$93.3K ﹤0.01% 9367
2020
Q2 		– Sell
-2,641
Closed -$10K – 10732
2020
Q1 		$10K Sell
2,641
-265
-9% -$1.37K ﹤0.01% 9427
2019
Q4 		$18K Buy
+2,906
New +$36.9K ﹤0.01% 8956

Other funds holding FSTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
CM
Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors's FSTX Position: Q4 2022 in Review

Citadel Advisors sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q4 2022, closing a stake of 49,708 shares — an estimated $255K sold.

Citadel Advisors first reported a position in FSTX in Q4 2019 and held it in 10 quarters. The position peaked at $3.8M in Q2 2021. 59 funds tracked by Wall St. Rank hold FSTX as of Q4 2022.

  • Citadel Advisors reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Citadel Advisors sold 49,708 F-star Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $255K.
  • Citadel Advisors first reported a position in F-star Therapeutics, Inc. Common Stock in Q4 2019 and held it in 10 quarters.
  • Citadel Advisors's F-star Therapeutics, Inc. Common Stock position peaked at $3.8M in Q2 2021.
  • 59 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.